Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Serono and Genmab sign worldwide antibody deal
Under the agreement, Genmab has granted Serono exclusive worldwide rights to develop and commercialize Genmab’s HuMax-TAC. Genmab will receive an upfront payment of $2 million and is entitled
Under the agreement, Genmab has granted Serono exclusive worldwide rights to develop and commercialize Genmab’s HuMax-TAC. Genmab will receive an upfront payment of $2 million and is entitled
GSK will pay $4.40 in cash for each share of Corixa common stock, or common stock equivalent, or approximately $300 million. Selected Corixa board members and their investment
Byetta (exenatide) injection is the first in a new class of medicines known as incretin mimetics and will be used to treat patients who have not achieved adequate
Exelixis believes that XL844 is the first potent, selective inhibitor of the checkpoint kinase pathway to progress to this stage of development. In addition to its therapeutic potential
The trial evaluated the performance of talabostat in combination with docetaxel in patients with stage IIIb/IV non-small cell lung cancer (NSCLC) who have not responded to platinum-based therapy.
Under the agreement, Avanir is eligible to receive over $200 million in upfront and milestone payments. Avanir is also eligible to receive increasing royalties on product sales in
The new license is in addition to an existing agreement between the companies that grants Genentech exclusive rights to use ImmunoGen’s technology with therapeutic antibodies to HER2. ImmunoGen’s
Using the company’s proprietary biochronomer bioerodible drug delivery system with granisetron, APF530 is designed to provide therapeutic levels of the drug in order to give four to five
The company is seeking marketing approval of Zegerid capsules as the first immediate-release proton pump inhibitor (PPI) in a capsule formulation for the treatment of heartburn and other
SkyePharma said it had agreed the main terms of a deal to help develop and market the respiratory medicine with an undisclosed party. The $160 million will include